Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
This expanded approval is a significant step forward for the Fabry community, as we work towards increasing awareness of this rare disease in young people.
- This expanded approval is a significant step forward for the Fabry community, as we work towards increasing awareness of this rare disease in young people.
- Progressive accumulation of GL-3 is believed to lead to the morbidity and mortality of Fabry disease, including pain, kidney failure, heart disease, and stroke.
- Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease.
- Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (